ScholarLens Back to search
2020•Current Problems in CancerRequires access

Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature

Rukiye Arıkan, Tuğba Akın Telli, Nazım Can Demircan, Tuğba Başoğlu, Özlem Erçelep, Beste M. Atasoy, Salih Özgüven, Faysal Dane, Perran Fulden Yumuk

Open publisher page 11 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Dabrafenib, Trametinib, Medicine, Anaplastic thyroid cancer, Oncology, Internal medicine, MEK inhibitor, Chemotherapy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature — Research Paper | ScholarLens